Cialis (Tadalafil) Manufacturing, Supply, and Shortage History

How Tadalafil Works: Mechanism Behind the Supply Demand

Tadalafil is a selective phosphodiesterase type 5 (PDE5) inhibitor that blocks the degradation of cyclic guanosine monophosphate (cGMP) in smooth muscle tissue. When sexual stimulation triggers nitric oxide release in the corpus cavernosum, cGMP accumulates and relaxes vascular smooth muscle, increasing penile blood flow [1]. The same pathway operates in the prostatic smooth muscle and bladder neck, which is why the FDA approved tadalafil 5 mg daily for benign prostatic hyperplasia (BPH) in 2011 [2].

What Makes Tadalafil Different from Other PDE5 Inhibitors

The 17.5-hour terminal half-life sets tadalafil apart from sildenafil (3 to 5 hours) and vardenafil (4 to 5 hours). Brock et al. Demonstrated in a randomized, double-blind trial (N=348) that tadalafil 10 mg and 20 mg doses produced statistically significant improvements in erectile function compared to placebo, with a therapeutic window extending to 36 hours post-dose [1]. That pharmacokinetic profile drove the "daily dosing" model and made tadalafil the only PDE5 inhibitor with a simultaneous BPH indication, a factor that has directly shaped manufacturing volumes and supply planning.

Clinical Demand Drivers

The dual indication (ED plus BPH) means tadalafil serves two large patient populations from the same production line. An estimated 30 million men in the U.S. Experience erectile dysfunction [3], and roughly 14 million carry a BPH diagnosis [2]. Daily-use prescriptions generate predictable, recurring demand, while on-demand 10 mg and 20 mg prescriptions create variable demand spikes. This demand profile has practical implications for inventory management across the supply chain.

From Discovery to FDA Approval: Tadalafil's Manufacturing Origins

Tadalafil's synthesis originated at ICOS Corporation in Bothell, Washington, during the early 1990s. ICOS partnered with Eli Lilly in 1998 to fund Phase III development. The FDA approved tadalafil (brand name Cialis) on November 21, 2003, for the treatment of erectile dysfunction [4]. Eli Lilly acquired ICOS outright in January 2007 for $2.3 billion, consolidating full manufacturing and commercial rights.

Early Production and Scale-Up

Eli Lilly manufactured tadalafil API and finished dosage forms at its facilities in Indianapolis, Indiana, and Kinsale, Ireland. The Kinsale site handled a significant share of global API production. Tablet finishing and packaging operations were split between Lilly's U.S. And European plants. By 2012, annual Cialis revenue exceeded $2 billion globally, requiring Lilly to scale API synthesis capacity well beyond the original clinical-supply infrastructure [5].

The BPH Expansion

FDA approval of tadalafil 5 mg for BPH in October 2011 expanded the addressable patient population and shifted manufacturing emphasis toward the lower-strength daily tablets. Lilly's 10-K filings from 2012 through 2016 show Cialis revenue climbing from $2.1 billion to $2.3 billion, driven primarily by daily-use prescriptions rather than on-demand use [5]. This shift required rebalancing tablet press allocation toward the 2.5 mg and 5 mg strengths.

Patent Expiration and the Generic Flood

Eli Lilly's compound patent for tadalafil was originally set to expire in November 2017. Lilly negotiated a settlement with several generic manufacturers that allowed limited generic entry starting September 27, 2018. However, a separate agreement with Actavis (now Teva) permitted the first authorized generic to launch in late 2017 [6].

The 2018 Generic Launch Wave

By mid-2018, multiple ANDA holders had received FDA approval to manufacture generic tadalafil tablets. Manufacturers included Teva, Aurobindo Pharma, Ajanta Pharma, Macleods Pharmaceuticals, Apotex, and Torrent Pharmaceuticals, among others. The FDA's Orange Book currently lists more than 15 approved generic tadalafil products across all four tablet strengths [7].

Price and Volume Effects

Generic entry compressed tadalafil pricing rapidly. Average wholesale acquisition cost for generic tadalafil 5 mg (30-count) dropped from approximately $370 (branded Cialis) to under $15 within 18 months of generic launch. IQVIA data from 2019 showed total tadalafil prescriptions (brand plus generic) increased 28% year-over-year, as lower prices expanded access [8]. The combination of price deflation and volume growth created margin pressure that some smaller generic manufacturers could not sustain, leading to periodic market exits and re-entries.

Active Pharmaceutical Ingredient Sourcing and the Global Supply Chain

Tadalafil API production is concentrated in India and China. The FDA's Drug Shortages database and inspection records indicate that the majority of generic tadalafil manufacturers source API from facilities in Hyderabad, Mumbai, and Gujarat (India), with secondary sourcing from Zhejiang and Jiangsu provinces (China) [9].

API Synthesis Overview

Tadalafil is synthesized through a multi-step process starting from D-tryptophan methyl ester and piperonal. The Pictet-Spengler condensation reaction forms the core tetrahydro-beta-carboline ring system. Subsequent steps involve chloroacetyl chloride acylation and ring closure to yield the methylenedioxyphenyl-substituted hydantoin. Final purification typically uses recrystallization from ethanol-water systems. The synthesis involves 5 to 7 steps depending on the manufacturer's route, and each step requires GMP-grade intermediates [10].

Supply Chain Vulnerabilities

Three structural weaknesses affect the tadalafil supply chain. First, the piperonal starting material is a DEA List I controlled chemical (it is also a precursor for MDMA synthesis), which means procurement requires regulatory documentation and can face intermittent restrictions [11]. Second, concentration of API manufacturing in two countries exposes supply to geopolitical disruption, as demonstrated during COVID-era shipping delays. Third, the low margins on generic tadalafil (relative to branded Cialis) reduce the economic incentive for manufacturers to maintain large buffer inventories.

FDA Shortage History: What Actually Happened

Tadalafil has experienced several documented supply disruptions since generic entry. The FDA Drug Shortage Database is the authoritative source for these events [12].

2020: COVID-Related Disruptions

During Q2 2020, the FDA reported tadalafil supply constraints across multiple manufacturers. The disruption was not unique to tadalafil. API shipments from India slowed after the Indian government imposed export restrictions on certain pharmaceutical intermediates in March 2020. Lupin and Aurobindo both reported manufacturing delays during this period. Supply normalized by Q4 2020 as Indian export controls were lifted and air freight capacity recovered [12].

2023: 20 mg Strength Shortage

In early 2023, several pharmacies reported difficulty sourcing generic tadalafil 20 mg tablets. The FDA listed tadalafil 20 mg as "currently in shortage" from approximately February through June 2023. Contributing factors included a demand surge (linked in part to telehealth prescribing growth and off-label use for pulmonary arterial hypertension) and a voluntary manufacturing pause at one mid-size ANDA holder due to a GMP compliance issue identified during FDA inspection [12]. The 2.5 mg and 5 mg daily-use strengths were not affected during this event.

Current Status

As of May 2026, the FDA Drug Shortage Database does not list tadalafil in any strength as "currently in shortage" [12]. Supply is stable across all four tablet strengths from multiple manufacturers. The American Society of Health-System Pharmacists (ASHP) drug shortage resource mirrors this assessment.

Quality and Regulatory Oversight of Generic Tadalafil

The FDA requires every generic tadalafil product to demonstrate bioequivalence to the Cialis reference listed drug (RLD) through in vivo pharmacokinetic studies. Bioequivalence is confirmed when the 90% confidence intervals for Cmax and AUC fall within 80% to 125% of the reference product [13].

Inspection and Compliance Record

FDA inspections of tadalafil manufacturing facilities have yielded a mixed compliance record. Between 2018 and 2025, the FDA issued Form 483 observations at several overseas API and finished dosage form plants producing tadalafil. Common findings included inadequate cleaning validation, insufficient data integrity controls, and incomplete deviation investigations [9]. No tadalafil-specific recalls related to safety or efficacy have occurred, though two voluntary Class III recalls (packaging/labeling errors) were issued for generic tadalafil products in 2019 and 2021.

Dissolution and Stability

The FDA's dissolution specification for tadalafil tablets requires not less than 80% (Q) dissolution in 30 minutes using 0.05M sodium lauryl sulfate medium. "Because tadalafil is a BCS Class II compound with low aqueous solubility, dissolution performance is the critical quality attribute that most directly predicts bioavailability," according to the FDA's product-specific bioequivalence guidance [14]. Manufacturers must demonstrate 36-month shelf-life stability under ICH conditions (25 degrees C / 60% RH) to support approved expiration dating.

Telehealth Prescribing and Its Effect on Demand Patterns

Telehealth-driven prescribing of tadalafil accelerated dramatically during 2020 and has not returned to pre-pandemic levels. A 2022 JAMA Network Open study found that telehealth encounters for erectile dysfunction increased 6-fold between January 2019 and December 2021 [15].

Volume Shifts

This prescribing pattern has two supply-chain effects. On-demand prescriptions (10 mg and 20 mg) have grown disproportionately through telehealth channels, partly because many telehealth platforms default to PRN dosing rather than daily regimens. The 20 mg strength is the most commonly dispensed tadalafil product in the U.S., accounting for an estimated 55% of total tadalafil prescriptions according to IQVIA 2024 dispensing data [8].

Compounding and 503B Outsourcing

A parallel supply channel has emerged through 503B outsourcing facilities that compound tadalafil in non-standard dosage forms (sublingual troches, combination products with sildenafil or oxytocin). These compounders source tadalafil API independently of the ANDA supply chain, adding a demand layer that traditional shortage tracking does not capture. The FDA has issued multiple warning letters to 503B facilities for tadalafil compounding violations, including one in November 2024 for inadequate sterility assurance in an injectable tadalafil product [16].

Tadalafil for Pulmonary Arterial Hypertension: A Separate Supply Track

Tadalafil 20 mg is also approved under the brand name Adcirca for pulmonary arterial hypertension (PAH), based on the PHIRST-1 trial (N=405), which demonstrated improved 6-minute walk distance at 40 mg daily dosing [17]. Adcirca is therapeutically identical to Cialis but is manufactured, packaged, and distributed through a separate supply chain managed by Eli Lilly's pulmonary division.

Cross-Indication Supply Interaction

Because Adcirca and generic tadalafil share the same API, shortages in one indication can theoretically affect the other. During the 2023 shortage event, some PAH patients on tadalafil 20 mg (two tablets daily for 40 mg total) experienced dispensing delays at specialty pharmacies. The Pulmonary Hypertension Association issued guidance recommending that PAH patients contact their specialty pharmacy 14 days before refill to allow time for sourcing [18].

What Patients Should Know About Current Tadalafil Supply

Generic tadalafil is widely available in the United States from more than 15 manufacturers across all four strengths. Patients who experience difficulty filling a prescription should ask their pharmacist to check alternative NDC codes from different manufacturers, as availability can vary by distributor. Switching between AB-rated generic tadalafil products does not require a new prescription or dose adjustment.

For patients on daily tadalafil 5 mg for BPH or ED, maintaining a 7-day buffer supply reduces the risk of treatment interruption during localized stock-outs. Prescribers using telehealth platforms should confirm that the dispensing pharmacy carries the prescribed strength before finalizing the e-prescription to avoid fulfillment delays.

The median out-of-pocket cost for generic tadalafil 5 mg (30 tablets) through GoodRx-participating pharmacies is currently $8 to $22, depending on the retailer and manufacturer [19].